Published in PLoS One on March 07, 2013
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair (2013) 1.27
Recent advances in quantitative LA-ICP-MS analysis: challenges and solutions in the life sciences and environmental chemistry. Anal Bioanal Chem (2015) 0.87
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity. Toxicol Lett (2015) 0.83
Techniques for measuring cellular zinc. Arch Biochem Biophys (2016) 0.82
Recent developments in multiplexing techniques for immunohistochemistry. Expert Rev Mol Diagn (2015) 0.78
Laser-induced breakdown spectroscopy: a new approach for nanoparticle's mapping and quantification in organ tissue. J Vis Exp (2014) 0.76
Simultaneous monitoring of cerebral metal accumulation in an experimental model of Wilson's disease by laser ablation inductively coupled plasma mass spectrometry. BMC Neurosci (2014) 0.76
Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Invest Radiol (2017) 0.75
Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease. J Cell Mol Med (2015) 0.75
Multi-Elemental Profiling of Tibial and Maxillary Trabecular Bone in Ovariectomised Rats. Int J Mol Sci (2016) 0.75
A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS. Anal Bioanal Chem (2016) 0.75
Diagnosis and treatment of Wilson disease: an update. Hepatology (2008) 4.79
Metal chelation and inhibition of bacterial growth in tissue abscesses. Science (2008) 4.55
Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med (2006) 3.84
Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82
Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology (2010) 2.17
Manganese and chronic hepatic encephalopathy. Lancet (1995) 1.47
Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am (2010) 1.37
Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet (1999) 1.36
Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis (2011) 1.29
Liver transplantation for Wilson's disease: indications and outcome. Hepatology (1994) 1.24
Non-HFE hepatic iron overload. Semin Liver Dis (2011) 1.20
Manganese intoxication and chronic liver failure. Ann Neurol (1994) 1.18
Advances in the understanding of mammalian copper transporters. Adv Nutr (2011) 1.17
Bioimaging of metals by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Mass Spectrom Rev (2009) 1.13
Trace metal imaging with high spatial resolution: applications in biomedicine. Metallomics (2010) 1.11
New developments in the regulation of intestinal copper absorption. Nutr Rev (2009) 1.09
Determination of the oxidation states of manganese in brain, liver, and heart mitochondria. J Neurochem (2004) 1.04
Iron overload in the liver diagnostic and quantification. Eur J Radiol (2006) 1.03
Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. J Viral Hepat (2011) 1.01
Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). J Am Soc Mass Spectrom (2009) 0.96
Zinc and the liver: an active interaction. Dig Dis Sci (2007) 0.95
Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol (2007) 0.94
Combined elemental and biomolecular mass spectrometry imaging for probing the inventory of tissue at a micrometer scale. Anal Chem (2012) 0.93
Iron disorders of genetic origin: a changing world. Trends Mol Med (2011) 0.93
Iron metabolism in Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep (2012) 0.90
Ultramicroanalysis: x-ray spectrometry by electron probe excitation. Annu Rev Biophys Bioeng (1977) 0.89
Iron and steatohepatitis. J Gastroenterol Hepatol (2012) 0.88
Manganese, copper, and zinc concentrations in serum and packed blood cells during acute hepatitis, chronic hepatitis, and posthepatitic cirrhosis. Clin Chem (1974) 0.86
Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomembr (2002) 0.83
The role of trace elements on hepatitis virus infections: a review. J Trace Elem Med Biol (2011) 0.82
Two-dimensional mapping of copper and zinc in liver sections by laser ablation-inductively coupled plasma mass spectrometry. Clin Chem (2003) 0.82
Copper deficiency exacerbates bile duct ligation-induced liver injury and fibrosis in rats. J Pharmacol Exp Ther (2011) 0.82
Can zinc enhance response interferon therapy for patients with HCV-related liver disease? World J Gastroenterol (2012) 0.81
Novel assessment of hepatic iron distribution by synchrotron radiation X-ray fluorescence microscopy. Med Mol Morphol (2010) 0.81
Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2013) 0.80
Zinc and other trace elements in liver cirrhosis. Ital J Gastroenterol (1992) 0.79
The effect of lead and cadmium on liver, kidney, and brain levels of cadmium, copper, lead, manganese, and zinc, and on erythrocyte ALA-D activity in mice. Bull Environ Contam Toxicol (1976) 0.78
Quantitative imaging of the tissue contrast agent [Gd(DTPA)]²⁻ in articular cartilage by laser ablation inductively coupled plasma mass spectrometry. Contrast Media Mol Imaging (2013) 0.78
Metals and the liver. Curr Opin Gastroenterol (2012) 0.77
Cadmium concentrations in human kidney and liver tissues from Western Australia. Bull Environ Contam Toxicol (1979) 0.77
Copper deficiency in sheep with high liver iron accumulation. Vet Med Int (2012) 0.77
Laser ablation ICP-MS Co-localization of mercury and immune response in fish. Environ Sci Technol (2011) 0.76
Roles of TGF-beta in hepatic fibrosis. Front Biosci (2002) 4.15
Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity (2007) 3.61
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 2.45
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta (2007) 2.10
miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol (2009) 2.06
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology (2011) 2.05
First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Efficient transfection method for primary cells. Tissue Eng (2002) 1.74
Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol (2013) 1.67
Serum proteomic profiling in patients with bladder cancer. Eur Urol (2009) 1.62
The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (2010) 1.59
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59
Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One (2011) 1.57
Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol (2008) 1.56
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells. Int J Mol Med (2011) 1.49
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. Oncogene (2005) 1.41
A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab (2007) 1.39
Atypical melting curve resulting from genetic variation in the 3' untranslated region at position 20218 in the prothrombin gene analyzed with the LightCycler factor II (prothrombin) G20210A assay. Clin Chem (2005) 1.31
Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis (2006) 1.29
Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol (2007) 1.26
Expression of hemoglobin in rodent neurons. J Cereb Blood Flow Metab (2008) 1.26
Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology (2012) 1.25
Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol (2007) 1.23
Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J (2006) 1.23
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut (2012) 1.22
Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest (2004) 1.22
Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol (2007) 1.22
Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. J Biol Chem (2007) 1.20
DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. Gastroenterology (2007) 1.18
Snail-regulated genes in malignant melanoma. Melanoma Res (2005) 1.17
Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol (2012) 1.17
Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol (2003) 1.17
Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch (2002) 1.16
Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest (2008) 1.16
Characterization of a novel human type II epithelial keratin K1b, specifically expressed in eccrine sweat glands. J Invest Dermatol (2005) 1.15
CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology (2010) 1.15
Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun (2004) 1.15
Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology (2013) 1.15
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep (2006) 1.14
miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol (2012) 1.13
Trace metal imaging with high spatial resolution: applications in biomedicine. Metallomics (2010) 1.11
Localization of the lipopolysaccharide recognition complex in the human healthy and inflamed premature and adult gut. Inflamm Bowel Dis (2010) 1.11
Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol (2008) 1.10
Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis (2007) 1.10
RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep (2013) 1.08
Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol (2003) 1.08
Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. Hepatology (2009) 1.07
Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther (2007) 1.07
Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol (2005) 1.07
Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology (2009) 1.07
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol (2007) 1.06
Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology (2012) 1.06
Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care (2007) 1.06
Aberrant cell cycle progression and endoreplication in regenerating livers of mice that lack a single E-type cyclin. Gastroenterology (2009) 1.06
Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function? J Cell Mol Med (2007) 1.06
A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol (2008) 1.05
Primary cultures of glomerular parietal epithelial cells or podocytes with proven origin. PLoS One (2012) 1.05
Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). Am J Pathol (2011) 1.04
H-cadherin expression reduces invasion of malignant melanoma. Pigment Cell Melanoma Res (2009) 1.04
Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int (2011) 1.04
Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes. Pigment Cell Res (2005) 1.04
Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. Melanoma Res (2007) 1.03
Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab Invest (2008) 1.03
Functional implication of Netrin expression in malignant melanoma. Cell Oncol (2009) 1.02
Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. Biochim Biophys Acta (2013) 1.02
Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care (2010) 1.02
Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ (2002) 1.02
Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and influences TGF-beta bioavailability. Biochim Biophys Acta (2007) 1.01
Identification of endoglin in rat hepatic stellate cells: new insights into transforming growth factor beta receptor signaling. J Biol Chem (2004) 0.99
Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio)adenosine on tumor progression of malignant melanoma. J Cell Biochem (2009) 0.99
Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano (2012) 0.98
Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark (2007) 0.98
Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal (2010) 0.97
Relevance of serum leptin and leptin-receptor concentrations in critically ill patients. Mediators Inflamm (2010) 0.96
Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med (2008) 0.96
Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). J Am Soc Mass Spectrom (2009) 0.96
Roles of AP-2 transcription factors in the regulation of cartilage and skeletal development. FEBS J (2009) 0.96
Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis. Fibrogenesis Tissue Repair (2010) 0.96
CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis (2013) 0.95
Factor VII activating protease (FSAP): a novel protective factor in liver fibrosis. Proteomics Clin Appl (2014) 0.95
Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest (2006) 0.95